Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orafar is a combination antiseptic and local anesthetic product developed and marketed by Pharmedic. It contains chlorhexidine gluconate, a biguanide antiseptic with broad-spectrum antimicrobial activity, and lidocaine hydrochloride, an amide-type local anesthetic. The product is designed for the local treatment of infections and inflammatory conditions of the oral cavity and pharynx, such as sore throat, gingivitis, and mouth ulcers. Chlorhexidine acts by disrupting microbial cell membranes, while lidocaine provides rapid pain relief by blocking voltage-gated sodium channels. Orafar is available in dosage forms including lozenges and sprays for topical application to the oral mucosa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorhexidine + lidocaine (Pharmedic).